Online Articles: Research ArticleExpression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer PatientsJespersen, Sofie S. MB*; Stovgaard, Elisabeth S. MD*; Nielsen, Dorte DMSc†; Christensen, Troels D. MD†; Buhl, Anna S.K. MD†; Christensen, Ib J. MSc*; Balslev, Eva MD* Author Information Departments of *Pathology †Oncology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark S.S.J. and E.S.S. contributed equally. S.S.J. received honoraria from the Medical Prognosis Institute. A.S.K.B. is currently employed at the Medical Prognosis Institute (now Oncology Venture), and her father is the CEO. The remaining authors declare no conflict of interest. Reprints: Sofie S. Jespersen, MB, Borgmester Ib Juuls Vej 1, Herlev, Copenhagen 2730, Denmark (e-mail: [email protected]). Applied Immunohistochemistry & Molecular Morphology: January 2021 - Volume 29 - Issue 1 - p e5-e9 doi: 10.1097/PAI.0000000000000854 Buy Metrics Abstract Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this group of enzymes are utilized in liposomal drug delivery of chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target in itself, and as a prognostic marker. The expression of sPLA2-IIa in breast cancer has not been examined extensively, and never using immunohistochemistry. We sought to investigate the expression of sPLA2-IIa in a cohort of advanced breast cancer patients with correlation to known clinicopathologic risk factors and survival. Material from 525 breast cancer patients (426 primary tumors and 99 metastases or local recurrences) was examined for sPLA2-IIa expression using immunohistochemistry. Out of these, 262 showed expression of sPLA2-IIa. We found that there was no correlation to clinicopathologic characteristics, and no impact of sPLA2-IIa expression on prognosis. However, we found that a large proportion of patients in our study had high levels of sPLA2-IIa expression, and that sPLA2-IIa was equally expressed in primary tumors and metastases. These findings may be significant in the future development of liposomal drug delivery or targeted sPLA2-IIa treatment. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.